|
9th Influenza Conference 2023
Scientific highlights of the 9th ESWI Influenza Conference
With promising developments in the field of respiratory viral infections, the conference sessions covered hot topics on seasonal, pandemic, and zoonotic influenza viruses, as well as other respiratory viruses such as RSV and SARS-CoV-2.
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant.
Is it bad, is it good, or is IgG4 just misunderstood?
Repeated doses of mRNA vaccines for COVID-19 result in increased proportions of anti-spike antibodies of the IgG4 subclass.
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022.
mRNA SARS-CoV-2 Vaccination Before vs During Pregnancy and Omicron Infection Among Infants
Infants younger than 6 months are at risk of severe SARS-CoV-2 infection.
|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
International scientific community gathers in Valencia for the 9th ESWI Conference on Influenza, COVID-19, and RSV
Since it was established 30 years ago, the European Scientific Working Group on Influenza and other Acute Respiratory Viruses (ESWI) is hosting the 9TH ESWI Influenza Conference
